Dianthus Therapeutics (NASDAQ:DNTH) Issues Earnings Results

Dianthus Therapeutics (NASDAQ:DNTH) posted its quarterly earnings results on Tuesday. The company reported ($0.81) earnings per share for the quarter, beating the consensus estimate of ($0.85) by $0.04, Zacks reports. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%.

Dianthus Therapeutics Trading Down 3.9 %

NASDAQ:DNTH traded down $0.96 during trading hours on Tuesday, reaching $23.38. 299,958 shares of the company were exchanged, compared to its average volume of 226,001. The stock’s 50-day moving average is $22.56 and its 200-day moving average is $25.02. Dianthus Therapeutics has a twelve month low of $18.13 and a twelve month high of $33.77. The firm has a market cap of $691.98 million, a PE ratio of -9.35 and a beta of 1.82.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on DNTH shares. Raymond James upgraded Dianthus Therapeutics to a “moderate buy” rating in a research report on Thursday, December 12th. Oppenheimer increased their price objective on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an “outperform” rating in a research note on Monday, November 11th. TD Cowen assumed coverage on shares of Dianthus Therapeutics in a research report on Friday, December 20th. They set a “buy” rating for the company. Finally, HC Wainwright reaffirmed a “buy” rating and set a $40.00 price target on shares of Dianthus Therapeutics in a research report on Monday, November 11th. Seven investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Dianthus Therapeutics currently has a consensus rating of “Buy” and an average price target of $46.83.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.